EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY-NC 4.0

A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US

Stewart J Tepper iD, Aaron Jenkins iD, Simon Dagenais, Carl Henriksen iD, Lucy Abraham iD, Feng Dai iD, Karin Hygge Blakeman iD, Astrid Gendolla

Cephalalgia · 2026-06 · 46 (6)

DOI: 10.1177/03331024261447187 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cephalalgia, online erschienen am 11.06.2026. Verfasst von Stewart J Tepper und 7 weiteren Autor:innen. Beteiligte Einrichtung: The New England Institute for Neurology and Headache, Stamford, Connecticut, USA. Hauptthemen laut MEDLINE: Piperidines, Migraine Disorders, Benzamides, Pyridines. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer UK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study compared treatment persistence of individuals newly initiating treatment with rimegepant or lasmiditan for the acute treatment of migraine.

Methods

A retrospective cohort analysis was conducted on individuals from MarketScan (commercial and managed Medicare) newly initiating treatment with rimegepant or lasmiditan between March 2020 and December 2022. Treatment persistence was defined as the proportion of individuals with ≥1 medication refill within 12 months of the index prescription. Subgroups included individuals with chronic migraine, index lasmiditan dose (50 and 100 mg) and individuals with a history of two or more uses of controlled substances (prior repeated use of controlled substances [PRUCS] defined here as opioids, butalbital, nausea medications with central nervous system action). Treatment persistence was compared between inverse probability of treatment weighting (IPTW)-adjusted cohorts using odds ratios (ORs) and 95% confidence intervals (CIs).

Results

The primary analysis included 16,603 rimegepant and 716 lasmiditan users. A significantly higher proportion of individuals in the rimegepant cohort were treatment persistent compared with the lasmiditan cohort (OR 3.79 [95% CI 3.23–4.41]). This finding remained consistent across lasmiditan dosages (50 mg: 5.05 [3.87–6.60]; 100 mg: 3.33 [2.78–4.00]), chronic migraine diagnosis (3.89 [3.21–4.71]), or PRUCS (ORs ranged from 2.78 to 4.63; all statistically significant).

Conclusion

Rimegepant users demonstrated higher treatment persistence over 12 months compared to lasmiditan users, which could reflect better real-world treatment satisfaction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PiperidinesMigraine DisordersBenzamidesPyridinesRetrospective StudiesHumansUnited StatesFemaleMaleMiddle AgedCohort Studies

Stichwörter der Autor:innen

acute treatmentlasmiditanmigrainepersistencereal-world datarimegepant

Substanzen

PiperidinesBenzamidesPyridineslasmiditan

Autor:innen und Institutionen

  • The New England Institute for Neurology and Headache, Stamford, Connecticut, USA.
  • Pfizer UK Ltd, Tadworth, Surrey, UK.
  • Pfizer Inc, New York, NY, USA.
  • Henriksen Analytic Insights, LLC, Gainesville, FL, USA.
  • Pfizer R&D UK Ltd, Tadworth, Surrey, UK.
  • Pfizer AB, Stockholm, Sweden.

ORCID-Profile: Stewart J Tepper, Aaron Jenkins, Carl Henriksen, Lucy Abraham, Feng Dai, Karin Hygge Blakeman

Förderung

  • Pfizer UK

Zitieren

APA

Tepper, S. J., Jenkins, A., Dagenais, S., Henriksen, C., Abraham, L., Dai, F., Hygge Blakeman, K., & Gendolla, A. (2026). A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US. Cephalalgia, 46(6). https://doi.org/10.1177/03331024261447187

Vancouver

Tepper SJ, Jenkins A, Dagenais S, Henriksen C, Abraham L, Dai F, et al. A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US. Cephalalgia. 2026;46(6). doi:10.1177/03331024261447187

BibTeX
@article{Tepper2026,
  author = {Tepper, Stewart J and Jenkins, Aaron and Dagenais, Simon and Henriksen, Carl and Abraham, Lucy and Dai, Feng and Hygge Blakeman, Karin and Gendolla, Astrid},
  title = {A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the US},
  journal = {Cephalalgia},
  year = {2026},
  volume = {46},
  number = {6},
  doi = {10.1177/03331024261447187}
}
Kostenlos starten →